Please login to the form below

Not currently logged in
Email:
Password:

Amicus Therapeutics launches Fabry treatment Galafold in Italy

Follows publication of Ministry of Health's reimbursement guidelines

Amicus TherapeuticsUS biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage.

Final reimbursement guidelines from the Ministry of Health back Galafold for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation.

John Crowley, Amicus chairman and CEO, said: "The commercial launch of Galafold in Italy is a significant milestone for the Fabry community.

“We believe that our successful pricing and reimbursement in Italy is a testament to the significant value of our oral precision medicine, and reflects our growing momentum with the country-by-country processes to launch Galafold throughout the EU.”

Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta).

Amicus’ therapy is a first-in-class chaperone therapy and works by stabilising the body's own dysfunctional enzyme.

Galafold received NICE backing for England and Wales last month and has been recommended as a treatment option in the US, on condition that Amicus provide it at a discounted rate.

Article by
Dominic Tyer

14th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics